Search Results

670 items found for "Strosberg AD"

Programs (1)

Advanced data analysis for GPCR pharmacology
Main objectives: - Learning how to perform advanced GPCR pharmacology data analysis in support of drug

Addex Raises $10 Million In Equity Financing
December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ”) at a gross purchase price of $6.50 per ADS, which is equivalent to CHF 1.00 per share. Each ADS represents six shares. Additionally, Addex has agreed to issue to Armistice Capital unregistered warrants to purchase up to The Unregistered Warrants have an exercise price of $6.50 per ADS, will become exercisable in 60 days
Addex raises $4.2 million in equity financing
July 2022 "Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based ”) at a gross purchase price of $1.70 per ADS, which is equivalent to CHF 0.27 per share. Each ADS represents six shares. The Unregistered Warrants have an exercise price of $1.90 per ADS, will become exercisable in 60 days
Adenosine receptor signalling in Alzheimer's disease
October 2022 "Alzheimer's disease (AD) is the most common dementia in the elderly and its increasing understanding of the disease, the current mainstay of treatment cannot modify pathogenesis or effectively address Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets The adenosine A1 and A2A receptors are expressed in the human brain and have a proposed involvement in

Ep 45 with Dr Ralf Jockers
Strosberg AD in France, where he worked on the regulation of ß-adrenergic receptors.
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
< GPCR News < GPCRs in Oncology and Immunology Phase 1/2 study of sorafenib added to cladribine, high-dose We quantified the kinetic antagonism between chemokines and hCCR3 before and after adding hCCR3 antagonists News Coming soon Become a Contributor Classified GPCR News Call for GPCR papers GPCR Industry News Adhesion
Session V | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program However, several ADGRs can be activated without GPS cleavage. competence of AD-GRB3/BAI3. Furthermore, conservation analysis indicates that wild type ADGRB2 and ADGRB3 are GPS cleavage-incompetent domains which couple cell adhesion to signaling.